David A. Siegel Tg Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 10,700 shares of TGTX stock, worth $459,993. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,700
Previous 225,500
95.25%
Holding current value
$459,993
Previous $5.27 Million
93.89%
% of portfolio
0.0%
Previous 0.01%
Shares
20 transactions
Others Institutions Holding TGTX
# of Institutions
373Shares Held
85.5MCall Options Held
3.78MPut Options Held
3M-
Vanguard Group Inc Valley Forge, PA15.6MShares$670 Million0.01% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$490 Million0.0% of portfolio
-
State Street Corp Boston, MA9.2MShares$396 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA3.19MShares$137 Million0.01% of portfolio
-
Pictet Asset Management Holding Sa Carouge, V82.79MShares$120 Million0.09% of portfolio
About TG THERAPEUTICS, INC.
- Ticker TGTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 145,274,000
- Market Cap $6.25B
- Description
- TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...